Loré Karin, Seggewiss Ruth, Guenaga F Javier, Pittaluga Stefania, Donahue Robert E, Krouse Allen, Metzger Mark E, Koup Richard A, Reilly Cavan, Douek Daniel C, Dunbar Cynthia E
Immunology Laboratory, Research Center, National Institute of Allergy and Infectious Diseases, NIH, Department of Health and Human Services, Bethesda, Maryland 20892-1202, USA.
Stem Cells. 2006 Jun;24(6):1539-48. doi: 10.1634/stemcells.2005-0455. Epub 2006 Feb 23.
Immunodeficiency after peripheral blood progenitor cell (PBPC) transplantation may be influenced by graft composition, underlying disease, and/or pre-treatment. These factors are difficult to study independently in humans. Ex vivo culture and genetic manipulation of PBPC grafts may also affect immune reconstitution, with relevance to gene therapy applications. We directly compared the effects of three clinically relevant autologous graft compositions on immune reconstitution after myeloblative total body irradiation in rhesus macaques, the first time these studies have been performed in a large animal model with direct clinical relevance. Animals received CD34(+) cell dose-matched grafts of either peripheral blood mononuclear cells, purified CD34(+) PBPCs, or purified CD34(+) PBPCs expanded in vitro and retrovirally transduced. We evaluated the reconstitution of T, B, natural killer, dendritic cells, and monocytes in blood and lymph nodes for up to 1 year post-transplantation. Animals receiving selected-transduced CD34(+) cells had the fastest recovery of T-cell numbers, along with the highest T-cell-receptor gene rearrangement excision circles levels, the fewest proliferating Ki-67(+) T-cells in the blood, and the best-preserved thymic architecture. Selected-transduced CD34(+) cells may therefore repopulate the thymus more efficiently and promote a higher output of naïve T-cells. These results have implications for the design of gene therapy trials, as well as for the use of expanded PBPCs for improved T-cell immune reconstitution after transplantation.
外周血祖细胞(PBPC)移植后的免疫缺陷可能受移植物组成、基础疾病和/或预处理的影响。在人类中很难独立研究这些因素。PBPC移植物的体外培养和基因操作也可能影响免疫重建,这与基因治疗应用相关。我们直接比较了三种临床相关的自体移植物组成对恒河猴清髓性全身照射后免疫重建的影响,这是首次在具有直接临床相关性的大型动物模型中进行此类研究。动物接受了外周血单个核细胞、纯化的CD34(+) PBPC或体外扩增并经逆转录病毒转导的纯化CD34(+) PBPC的CD34(+)细胞剂量匹配移植物。我们评估了移植后长达1年血液和淋巴结中T细胞、B细胞、自然杀伤细胞、树突状细胞和单核细胞的重建情况。接受选定转导的CD34(+)细胞的动物T细胞数量恢复最快,T细胞受体基因重排切除环水平最高,血液中增殖的Ki-67(+) T细胞最少,胸腺结构保存最好。因此,选定转导的CD34(+)细胞可能更有效地重新填充胸腺并促进更高水平的初始T细胞输出。这些结果对基因治疗试验的设计以及移植后使用扩增的PBPC改善T细胞免疫重建具有重要意义。